Login to My NLA Account

Every 39 seconds, a U.S. adult dies from cardiovascular disease (CVD),1  the nation’s top killer and a leading cause of disability for Americans both young and old. We spend about 1 out of 6 healthcare dollars on this disease each year — an estimated nearly $320 billion in healthcare expenses and lost productivity.1 But those human and economic costs could be lower if we expanded our national actions in prevention.

Article By:

JANET S. WRIGHT, MD, FACC
Executive Director
Million Hearts Initiative
Washington, D.C.

0
No votes yet

In the strictest sense, “advocacy” is defined as the act or process of supporting a cause. With that as the basis of our discussion, why is advocacy important to a medical specialty organization such as the National Lipid Association (NLA)?

Article By:

M. EUGENE SHERMAN, MD, FACC
Chair, Advocacy Steering Committee
American College of Cardiology
Centennial, CO

0
No votes yet

I’ve been through many stages with the guidelines. I really think I love them now. Let me tell you why.

Article By:

DANIEL E. SOFFER, MD, FNLA
Clinical Associate Professor of Medicine
University of Pennsylvania
Internal Medicine and Preventive Cardiology
University of Pennsylvania Health System
Philadelphia, PA

Diplomate, American Board of Clinical Lipidology

0
No votes yet

“If you would not be forgotten as soon as you are dead and rotten, either write things worth reading or do things worth the writing.” – Benjamin Franklin

Article By:

THOMAS A. HAFFEY, DO, FACC, FACOI, FNLA

President, Southwest Lipid Association
Clinical Professor, Western University/COMP
Denver, CO

 

Diplomate, American Board of Clinical Lipidology

0
No votes yet

How many of you have taken the time to read, from front to back, the recent National Lipid Association (NLA) Recommendations for Patient-Centered Management of Dyslipidemia, Parts 1 and 2? Don’t be embarrassed, because I can’t see how few of you raised your hands.

Article By:

CARL E. ORRINGER, MD, FACC, FNLA
President, National Lipid Association
Associate Professor of Medicine
University of Miami School of Medicine
Director, Lipid Clinic and Cardiovascular Risk Reduction Program
Miami, FL

Diplomate, American Board of Clinical Lipidology

0
No votes yet
Last Updated: Tuesday, 08-Mar-2016 17:00:00 EST

By Carol Kirkpatrick, PhD, RDN, LDN, CLS, FNLA; Geeta Sikand, MA, RDN, FAND, CLS, CDE, FNLA; Ralph LaForge, MSc, CLS, FNLA

In September, the National Lipid Association released its new Recommendations for Patient-Centered for Dyslipidemia Management – Part 2. These recommendations include a thorough review of the lifestyle therapies — nutrition and physical activity — that promote atherosclerotic CVD risk reduction through lowering atherogenic cholesterol and other atherosclerotic CVD risk factors.

Targets of lifestyle therapies

Last Updated: Monday, 22-Feb-2016 17:00:00 EST

The National Lipid Association's (NLA) Annual Summary of Clinical Lipidology 2016 was just published the Journal of Clinical Lipidology.

Last Updated: Wednesday, 17-Feb-2016 17:00:00 EST

National Lipid Association, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association Agree Bariatric Surgery Produces Positive Effects

Last Updated: Monday, 08-Feb-2016 17:00:00 EST

The 2nd annual Pfizer ASPIRE Cardiovascular Grants Program offers individual grants from a total fund of US $2 million — Apply now! 

Are you or any of your collaborators involved in PCSK9-related research and looking for funding to support your work?